[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Roche Holding Ltd ADR (RHHBY)

Roche Holding Ltd ADR (RHHBY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 329,739,040
  • Shares Outstanding, K 6,370,538
  • Annual Sales, $ 76,471 M
  • Annual Income, $ 15,546 M
  • EBIT $ 0 M
  • EBITDA $ 26,387 M
  • 60-Month Beta 0.50
  • Price/Sales 4.35
  • Price/Cash Flow 14.49
  • Price/Book 7.27
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 01/29/26
  • Annual Dividend & Yield (Fwd) 0.97 (1.86%)
  • Most Recent Dividend 0.972 on 03/13/26
  • Sector Medical
  • INDUSTRY GROUPING Large Cap Pharma

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
49.0000 +6.16%
on 06/22/26
53.4967 -2.76%
on 07/02/26
+1.7900 (+3.56%)
since 06/09/26
3-Month
48.1000 +8.15%
on 06/02/26
53.5400 -2.84%
on 05/22/26
+1.7100 (+3.40%)
since 04/09/26
52-Week
37.5100 +38.68%
on 08/11/25
60.8500 -14.51%
on 02/24/26
+11.1500 (+27.28%)
since 07/09/25

Most Recent Stories

More News
The Market Just Got Shaken—These 3 ETFs May Come Out Stronger

As Middle East tensions resurface and futures drop, VIG, VIGI, and FDVV offer dividend growth ETFs combining income with exposure to technology and global equities.

NVDA : 202.78 (-0.66%)
AAPL : 316.22 (+0.90%)
AVGO : 401.11 (+3.20%)
SAP : 158.46 (+0.66%)
JNJ : 259.10 (-1.63%)
RY : 208.56 (+1.36%)
NVS : 154.62 (-0.35%)
RHHBY : 52.0200 (+0.50%)
NSRGY : 103.1100 (-0.37%)
SBGSY : 61.6900 (+1.41%)
MSFT : 384.36 (+0.27%)
VIG : 238.62 (+0.51%)
Genentech and Roche Present New Data in Alzheimer’s Disease From Across Its Integrated Pharmaceutical and Diagnostics Portfolio at AAIC

Five oral presentations in a Featured Research Session will highlight trontinemab, including new long-term data from Phase Ib/IIa Brainshuttle AD study and design of Phase III PrevenTRON study in preclinical...

RHHBY : 52.0200 (+0.50%)
Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer

Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer Divarasib...

RHHBY : 52.0200 (+0.50%)
FDA Grants Priority Review To Genentech’s Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)

The filing application is based on improvements seen across key efficacy endpoints from the global Phase III SatraGO-1 and SatraGO-2 studies, including proptosis (bulging eyes) and diplopia (double vision)...

RHHBY : 52.0200 (+0.50%)
1 of the Most Interesting AI Stocks in the Market Isn’t a Tech Company

Recursion Pharmaceuticals is trying to prove that AI’s next big winner can also come from biotech, and not just from the tech sector.

RXRX : 3.76 (+1.08%)
RHHBY : 52.0200 (+0.50%)
SNY : 43.90 (+2.62%)
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.

QNTM : 3.41 (+4.28%)
QNTM.CN : 4.8100 (+8.09%)
CLNN : 6.25 (+2.80%)
RHHBY : 52.0200 (+0.50%)
SNY : 43.90 (+2.62%)
BIIB : 198.91 (-0.72%)
FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma

– Filing acceptance based on data from the Phase III SUNMO study where subcutaneous Lunsumio VELO plus Polivy demonstrated a 59% reduction in risk of disease progression or death – ...

RHHBY : 52.0200 (+0.50%)
FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer

Filing acceptance is based on the Phase III Alliance ATOMIC study showing Tecentriq plus chemotherapy reduced recurrence or death risk by 50% versus chemotherapy alone ...

RHHBY : 52.0200 (+0.50%)
Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies

TUCSON, Ariz. , June 11, 2026 /PRNewswire/ -- Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the European Union In Vitro Diagnostic Regulation (IVDR) approval of several label expansions for...

ROP : 355.94 (+0.30%)
RHHBY : 52.0200 (+0.50%)
Nuvalent Stock Hits All-Time High Following GSK's Buyout Offer

Nuvalent shares soar as GSK announces a $10.6 billion buyout deal. But is it too late already to invest in NUVL stock?

NUVL : 123.83 (+0.02%)
RHHBY : 52.0200 (+0.50%)
GSK : 52.47 (-0.10%)
PFE : 24.25 (+0.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its...

See More

Key Turning Points

3rd Resistance Point 52.9200
2nd Resistance Point 52.5800
1st Resistance Point 52.3000
Last Price 52.0200
1st Support Level 51.6800
2nd Support Level 51.3400
3rd Support Level 51.0600

See More

52-Week High 60.8500
Last Price 52.0200
Fibonacci 61.8% 51.9341
Fibonacci 50% 49.1800
Fibonacci 38.2% 46.4259
52-Week Low 37.5100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.